Introduction {#Sec1}
============

Anxiety and mood disorders are major contributors to the global disease burden \[[@CR1]\] due partly to their high prevalence \[[@CR2]\], early onset \[[@CR3]\], and chronic or recurrent course \[[@CR4]--[@CR6]\]. Although much effort has been devoted to improving the course of these disorders, treatment is still insufficient to avert most of the burden \[[@CR7]--[@CR11]\]. Consequently, prevention may be a necessary alternative strategy.

Comorbidity between mental disorders is common \[[@CR12], [@CR13]\], which has led theorists to posit a latent structure of psychopathology, reducing a variety of disorders to a limited set of domains \[[@CR14]\]. These domains, of which the internalizing and externalizing have been confirmed most frequently \[[@CR15]--[@CR20]\], are thought to represent core psychopathological processes underlying the varied clinical manifestations of disorders. If so, targeting these underlying processes might offer new opportunities for prevention. Internalizing disorders, for example, develop at very different ages: specific phobia (SP) has a median age of onset at 8 years old \[[@CR21]\], whereas major depressive disorder (MDD) and generalized anxiety disorder (GAD) have median onset at 30--40 years old \[[@CR3], [@CR22]\]. If interventions could successfully treat the earlier disorders in this domain, this might lead to reductions in the subsequent onset, persistence, or severity of other disorders in the same domain.

Although SP is often considered a relatively mild disorder \[[@CR23], [@CR24]\], the structure of psychopathology model suggests that it might identify persons with a vulnerability for more serious later disorders in the same domain. In support of this possibility, SP has been associated with increased risk of later-onset disorders in the internalizing domain \[[@CR21], [@CR25]--[@CR34]\]. Importantly, persons with SP may have only a single fear, or they may have many (e.g., of spiders, storms, blood, and heights). Some evidence suggests that persons with multiple fears have a greater risk of comorbidity and impairment \[[@CR21], [@CR29], [@CR33], [@CR35], [@CR36]\], suggesting that g*eneralized* SP may be a marker of particularly high internalizing vulnerability.

With an eye toward early intervention, SP *with an onset in childhood* is of greatest interest, but to date, no study has examined internalizing comorbidity in this group of people. Furthermore, information about other important aspects of comorbidity, such as age of onset, persistence, and severity, and other outcomes, such as suicidality, is largely lacking. In this paper, we therefore examine these outcomes. We focus on the number of phobia subtypes as a marker of generalization of the underlying psychopathological process, expecting worse outcomes among persons reporting more fears.

Methods {#Sec2}
=======

Survey samples {#Sec3}
--------------

Data came from the World Mental Health Surveys (WMHS), which include cross-sectional surveys administered in low/lower-middle-income countries, upper-middle-income countries, and high-income countries (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Adults were selected using probability sampling methods designed to generate population representative samples, and interviews were conducted face to face in respondent homes. A total of 123,628 respondents from 25 countries participated in the present study. Informed consent was obtained according to protocols endorsed by local Institutional Review Boards. Within-country sampling methods are described in detail elsewhere \[[@CR37], [@CR38]\].

Measures {#Sec4}
--------

### Mental disorders {#Sec5}

Lifetime and 12-month mental disorders were assessed with the WHO Composite International Diagnostic Interview (CIDI) \[[@CR39]\]. To reduce respondent burden, interviews were administered in two parts. All respondents completed part I, assessing core mental disorders. Part II, assessing other disorders and correlates, was administered to all respondents with any lifetime part I diagnosis and a probability subsample of other part I respondents. Part II data were weighted so that weighted prevalence estimates are identical to those in the part I sample.

We included the following internalizing disorders: anxiety disorders (panic disorder, agoraphobia, GAD, social anxiety disorder, SP, post-traumatic stress disorder \[PTSD\], separation anxiety disorder), mood disorders (MDD and/or dysthymia, bipolar disorder \[I, II, or subthreshold\]), and eating disorders (bulimia nervosa, binge eating disorder). CIDI diagnoses have shown generally good concordance with diagnoses based on blinded Structured Clinical Interview for DSM-IV (SCID) reappraisal \[[@CR40]\]. Age of onset was assessed with retrospective reports. Persistence was defined as the presence of the disorder in the 12 months before interview among lifetime cases.

### Specific phobia {#Sec6}

The CIDI distinguishes between six SP subtypes: animals, still water or weather, high places, blood-injection-injury, closed spaces, and flying. For each participant, we determined how many subtypes with an age of onset prior to age 13 were reported. Because few participants reported more than four subtypes, we collapsed participants reporting four or more subtypes into a single group. Participants who developed SP later in life were included in the group of participants without childhood SP.

### Impairment and suicidality {#Sec7}

Severe role impairment due to SP was assessed with a modified Sheehan Disability Scale (SDS) \[[@CR41]\]. Respondents with 12-month SP rated its interference with functioning in four domains (home management, work, close relationships, and social life) on a scale of 0--10 during the worst month in the past year. Severe impairment was defined as a score ≥ 7 in at least one domain. Respondents with lifetime SP were asked whether they had ever sought treatment specifically for SP.

All respondents were asked how many days in the past 30 days they were totally unable to work or carry out normal activities because of any physical or mental health problems, whether they had ever seriously thought about committing suicide, and, if so, whether they had ever made a plan or attempted suicide. We also examined serious mental illness (SMI), which was defined as meeting criteria for 12-month bipolar I disorder or having another 12-month mood or anxiety disorder (other than SP) with either severe role impairment or a past-year suicide attempt \[[@CR42]\].

### Statistical analysis {#Sec8}

We tested the linear association of the number of early-onset SP subtypes, both within the whole sample and within the subsample with childhood SP, using logistic regression for dichotomous variables and linear regression for continuous variables (SAS 9.4). We used the actuarial method to determine the age of onset of comorbid disorders and tested for differences in age of onset depending on the number of SP subtypes using discrete-time logistic regression in the subsample with the comorbid disorder. We also used the actuarial method to calculate the projected lifetime risk of any internalizing disorder, which takes into account that respondents who have not had a disorder yet may still develop the disorder later in life. We also estimated population attributable fractions (PAFs) \[[@CR43]\], which indicate the fraction of an outcome in the population that is attributable to childhood SP (assuming a causal relationship, noting that the latter can only be confirmed experimentally). All analyses controlled for country of origin of the participant. Because the data were clustered and weighted, standard errors were estimated using the Taylor series linearization method (SUDAAN 11.0.1). Significance tests were evaluated using *α* = 0.005 (two-sided) to reduce the chance of false-positive findings given the many tests performed.

As sensitivity analyses, we tested interactions between the number of SP subtypes and age group (18--34, 35--49, and 50+ years old), to examine whether associations between childhood phobia and mental health outcomes persisted into older adulthood. We also tested whether associations were found for participants with and without current internalizing psychopathology and for participants from high-income countries as well as those from low- or middle-income countries.

Results {#Sec9}
-------

Specific phobia {#Sec10}
---------------

Out of 123,628 participants, 51.8% were female and the mean age was 42.0 (SD = 16.9). Lifetime and 12-month SP prevalence was 7.6% and 5.7%, respectively. Most respondents reported onset before the age of 13, resulting in a 5.9% lifetime prevalence of childhood-onset SP. Prevalence was 3.3% for one early-onset subtype, 1.5% for two, 0.6% for three, and 0.5% for 4+ (Table [1](#Tab1){ref-type="table"}). Persistence was high and increased with number of subtypes (from 73.4% for participants with one subtype to 85.2% for those with 4+ subtypes, OR = 1.2, *p* \< 0.001). Severe impairment due to SP and treatment for SP were uncommon (17.5--26.5%), but increased with an increasing number of subtypes (OR = 1.1--1.3, *p* = 0.004 and \< 0.001).Table 1Prevalence and characteristics of specific phobiaAny specific phobiaAny early-onset specific phobiaNumber of subtypesTest of linear effect1234+% (SE)% (SE)% (SE)% (SE)% (SE)% (SE)OR (95% CI)*p* valueLifetime prevalence7.6 (0.1)5.9 (0.1)3.3 (0.1)1.5 (0.0)0.6 (0.0)0.5 (0.0)----12-month prevalence5.7 (0.1)4.4 (0.1)2.4 (0.1)1.1 (0.0)0.5 (0.0)0.4 (0.0)----Persistence74.3 (0.6)75.2 (0.7)73.4 (0.9)75.2 (1.3)77.6 (1.8)85.2 (1.8)1.2\* (1.1--1.3)\< 0.001Severe disability19.1 (0.6)19.7 (0.6)17.5 (0.8)20.2 (1.4)24.0 (2.0)26.5 (2.4)1.3\* (1.1--1.4)\< 0.001Treatment for specific phobia22.4 (0.5)20.8 (0.6)19.1 (0.8)22.9 (1.2)22.4 (1.7)22.8 (2.0)1.1\* (1.0--1.2)0.004\**p* \< 0.005

Internalizing disorder comorbidity {#Sec11}
----------------------------------

Lifetime prevalence of any internalizing disorder increased from 18.2% among those without childhood SP to 46.3% among those with one SP subtype and 75.6% among those with 4+ subtypes (OR = 2.4 in the total sample and 1.6 in the SP subsample, *p* \< 0.001) (Table [2](#Tab2){ref-type="table"}). Figure [1](#Fig1){ref-type="fig"} shows the projected risk of any internalizing disorder by age and number of SP subtypes. Examining separate disorder groupings, similar patterns were apparent for anxiety disorders (OR = 2.4 (total sample) and 1.6 (SP subsample), *p* \< 0.001), mood disorders (OR = 1.9 (total sample) and 1.4 (SP subsample), *p* \< 0.001), and eating disorders (OR = 1.8 (total sample) and 1.3 (SP subsample), *p* \< 0.001 and *p* = 0.003). Only 0.6% of respondents without SP and 4.2% of those with one SP subtype met criteria for 4+ internalizing disorders (other than SP), compared to 19.4% of respondents with 4+ SP subtypes (OR = 2.6 (total sample) and 1.7 (SP subsample), *p* \< 0.001). SP preceded other internalizing disorders in 79.4% of comorbid cases; in an additional 10.8% of cases, the onset of SP and another internalizing disorder coincided.Table 2Prevalence of comorbid internalizing disorders, as a function of the number of specific phobia subtypesComorbid disorderNumber of subtypesTest of linear effect (total sample)Test of linear effect (SP cases only)01234+% (SE)% (SE)% (SE)% (SE)% (SE)OR (95% CI)*p* valueOR (95% CI)*p* valueAgoraphobia0.8 (0.0)5.1 (0.4)9.5 (0.8)17.4 (2.0)21.2 (2.3)2.6\* (2.4--2.7)\< 0.0011.7\* (1.5--1.9)\< 0.001Generalized anxiety disorder3.5 (0.1)9.7 (0.6)14.2 (1.1)21.0 (1.8)21.3 (2.6)1.8\* (1.7--1.9)\< 0.0011.4\* (1.3--1.5)\< 0.001Panic disorder1.4 (0.0)5.5 (0.5)8.8 (0.7)12.6 (1.5)15.8 (1.8)2.0\* (1.9--2.1)\< 0.0011.5\* (1.3--1.6)\< 0.001Post-traumatic stress disorder2.9 (0.1)9.0 (0.6)15.3 (1.2)18.5 (1.8)22.2 (2.3)1.9\* (1.8--2.0)\< 0.0011.4\* (1.3--1.6)\< 0.001Separation anxiety disorder3.9 (0.1)12.7 (0.9)19.7 (1.7)27.2 (2.5)27.4 (2.7)1.9\* (1.8--2.0)\< 0.0011.4\* (1.2--1.5)\< 0.001Social anxiety disorder3.3 (0.1)14.9 (0.8)23.2 (1.3)31.3 (2.3)38.2 (2.8)2.3\* (2.2--2.4)\< 0.0011.5\* (1.4--1.6)\< 0.001*Any anxiety disorder10.5 (0.2)33.6 (1.1)47.0 (1.7)62.4 (2.3)66.1 (2.8)2.4\* (2.3--2.5)\< 0.0011.6\* (1.5--1.7)\< 0.001*Major depression/dysthymia10.5 (0.2)24.1 (0.9)30.1 (1.4)36.2 (2.5)34.1 (2.7)1.6\* (1.6--1.7)\< 0.0011.2\* (1.2--1.3)\< 0.001Bipolar disorder1.8 (0.1)5.7 (0.5)10.0 (0.9)12.7 (1.5)17.3 (1.9)1.9\* (1.8--2.0)\< 0.0011.5\* (1.3--1.6)\< 0.001*Any mood disorder12.0 (0.2)28.8 (1.0)39.3 (1.5)47.8 (2.5)50.9 (3.0)1.9\* (1.8--1.9)\< 0.0011.4\* (1.3--1.5)\< 0.001*Bulimia nervosa0.6 (0.0)2.0 (0.3)3.6 (0.7)6.8 (1.6)5.9 (1.6)2.0\* (1.8--2.2)\< 0.0011.7\* (1.4--2.0)\< 0.001Binge eating disorder1.4 (0.1)5.7 (0.8)5.3 (0.8)6.6 (1.7)6.3 (1.7)1.7\* (1.5--1.8)\< 0.0011.0 (0.8--1.3)0.746*Any eating disorder1.9 (0.1)7.2 (0.9)8.3 (1.0)12.4 (2.0)11.4 (2.2)1.8\* (1.7--1.9)\< 0.0011.3\* (1.1--1.5)0.003Any internalizing disorder18.2 (0.2)46.3 (1.2)61.1 (1.7)75.6 (2.1)75.6 (2.7)2.4\* (2.3--2.5)\< 0.0011.6\* (1.5--1.8)\< 0.001*Exactly 1 internalizing disorder12.3 (0.2)24.0 (1.0)27.6 (1.5)26.8 (2.2)21.6 (2.4)1.4\* (1.3--1.4)\< 0.0011.0 (0.9--1.1)0.677Exactly 2 internalizing disorders4.0 (0.1)12.2 (0.7)15.2 (1.2)21.6 (2.0)19.7 (2.2)1.7\* (1.6--1.8)\< 0.0011.2\* (1.1--1.3)\< 0.001Exactly 3 internalizing disorders1.4 (0.0)5.9 (0.5)9.2 (0.8)12.8 (1.5)14.9 (1.8)2.0\* (1.9--2.1)\< 0.0011.4\* (1.2--1.5)\< 0.0014+ internalizing disorders0.6 (0.0)4.2 (0.4)9.0 (0.8)14.4 (1.7)19.4 (2.6)2.6\* (2.4--2.8)\< 0.0011.7\* (1.6--2.0)\< 0.001Italics indicate the main groups of disorders. \**p* \< 0.005Fig. 1Projected risk of any internalizing disorder by age 75, by number of childhood specific phobia subtypes. Projected risk was calculated using the actuarial method and accounts for censoring of participants who have not yet reached the age of 75 by the time of the interview

Estimated PAFs for any childhood SP ranged from 8.7% for MDD to 38.8% for agoraphobia (Additional file [1](#MOESM1){ref-type="media"}: Table S2). This means that if the associations found here are accurate reflections of causal effects either of childhood SP or of a latent liability that could be successfully treated by early intervention with childhood SP, the population-level lifetime prevalence of these disorders would be expected to decrease proportionally by 8.7--38.8%. The PAFs for any internalizing disorder and for 4+ internalizing disorders were 10.2% and 39.4%, respectively.

Persistence of any lifetime internalizing disorder increased from 47.9% for respondents without childhood SP to 59.0% for those with one SP subtype and 79.1% for those with 4+ subtypes (OR = 1.4 (total sample) and 1.3 (SP subsample), *p* \< 0.001) (Table [3](#Tab3){ref-type="table"}). Examining separate disorder groupings, similar patterns were found for anxiety disorders (OR = 1.4 (total sample) and 1.2 (SP subsample), *p* \< 0.001) and mood disorders (OR = 1.3 (total sample) and 1.2 (SP subsample), *p* \< 0.001), but not for eating disorders (OR = 1.1 (total sample) and 0.8 (SP subsample), *p* = 0.164--0.295).Table 3Persistence of comorbid internalizing disorders, as a function of the number of specific phobia subtypesComorbid disorderNumber of subtypesTest of linear effect (total sample)Test of linear effect (SP cases only)01234+% (SE)% (SE)% (SE)% (SE)% (SE)OR (95% CI)*p* valueOR (95% CI)*p* valueAgoraphobia57.8 (2.6)67.6 (3.9)64.6 (5.1)63.6 (6.6)86.4 (3.2)1.3\* (1.1--1.4)\< 0.0011.3\* (1.1--1.6)0.002Generalized anxiety disorder46.2 (1.1)52.3 (3.0)56.3 (3.7)51.0 (4.7)68.7 (5.3)1.2\* (1.1--1.3)\< 0.0011.1 (1.0--1.3)0.155Panic disorder56.1 (1.9)59.3 (4.1)65.7 (3.9)63.6 (5.8)80.7 (4.7)1.2\* (1.1--1.4)\< 0.0011.3\* (1.1--1.6)0.003Post-traumatic stress disorder46.0 (1.5)53.4 (3.5)56.0 (4.0)59.6 (4.9)50.9 (5.4)1.2\* (1.0--1.3)0.0031.0 (0.9--1.2)0.821Separation anxiety disorder20.4 (1.3)20.3 (3.1)24.2 (3.1)23.3 (4.2)26.3 (4.3)1.1 (1.0--1.2)0.1091.1 (0.9--1.3)0.345Social anxiety disorder56.2 (1.3)65.3 (2.7)73.9 (2.8)73.4 (3.6)80.2 (3.5)1.3\* (1.2--1.5)\< 0.0011.2 (1.0--1.3)0.027*Any anxiety disorder48.9 (0.8)59.5 (1.8)65.4 (2.1)65.5 (2.9)76.0 (2.9)1.4\* (1.3--1.4)\< 0.0011.2\* (1.1--1.3)\< 0.001*Major depression/dysthymia39.7 (0.6)48.8 (2.0)51.5 (2.7)56.3 (3.8)63.3 (4.5)1.3\* (1.2--1.4)\< 0.0011.2 (1.0--1.3)0.007Bipolar disorder56.7 (1.6)57.4 (4.3)67.9 (4.8)70.2 (5.4)77.5 (4.9)1.2\* (1.1--1.4)\< 0.0011.4\* (1.2--1.8)0.001*Any mood disorder41.9 (0.5)50.2 (1.8)55.3 (2.4)59.7 (3.1)68.0 (3.3)1.3\* (1.2--1.4)\< 0.0011.2\* (1.1--1.4)\< 0.001Any eating disorder42.9 (2.3)54.0 (5.7)55.7 (5.7)38.1 (8.8)45.1 (8.9)1.1 (0.9--1.2)0.2950.8 (0.6--1.1)0.164Any internalizing disorder47.9 (0.5)59.0 (1.5)66.1 (2.0)70.5 (2.5)79.1 (2.5)1.4\* (1.4--1.5)\< 0.0011.3\* (1.2--1.4)\< 0.001*Persistence is defined as the presence of a 12-month disorder among lifetime cases with that disorder. Because of low prevalence, persistence of individual eating disorders was not assessedItalics indicate the main groups of disorders. \**p* \< 0.005

Median age of onset of comorbid internalizing disorders generally decreased with increasing number of early-onset SP subtypes (Table [4](#Tab4){ref-type="table"}), especially for agoraphobia, GAD, panic disorder, and MDD/dysthymia. For GAD, median age of onset was 39 for those without childhood SP, 37 for those with one subtype, and 28 for those with 4+ subtypes (OR = 1.2 (total sample and SP subsample), *p* \< 0.001). Similarly, median age of onset decreased from 21 to 12 for agoraphobia, from 33 to 18 for panic disorder, and from 38 to 29 for MDD/dysthymia (OR = 1.2 (total sample) and 1.1--1.3 (SP subsample), *p* \< 0.001). For social anxiety disorder, there was also a consistent, though slight, decrease in age of onset with an increasing number of SP subtypes (from 14 to 12, OR = 1.2 (total sample) and 1.3 (SP subsample), *p* \< 0.001). For PTSD, separation anxiety disorder, and bipolar disorder, patterns were less consistent (OR = 1.0--1.2, *p* \< 0.001--0.235).Table 4Age of onset of comorbid disorders, as a function of the number of specific phobia subtypesComorbid disorderNumber of subtypesTest of linear effect (whole sample)Test of linear effect (SP cases only)01234+Median (IQR)Median (IQR)Median (IQR)Median (IQR)Median (IQR)OR (95% CI)*p* valueOR (95% CI)*p* valueAgoraphobia21 (13--35)21 (13--39)20 (13--40)16 (8--31)12 (8--17)1.2\* (1.1--1.2)\< 0.0011.3\* (1.2--1.4)\< 0.001Generalized anxiety disorder39 (26--54)37 (24--52)35 (21--52)33 (20--44)28 (18--46)1.2\* (1.1--1.2)\< 0.0011.2\* (1.1--1.2)\< 0.001Panic disorder33 (21--49)29 (19--41)35 (18--60)24 (14--41)18 (11--27)1.2\* (1.2--1.3)\< 0.0011.2\* (1.1--1.3)\< 0.001Post-traumatic stress disorder36 (21--54)33 (20--49)36 (19--53)35 (19--75)33 (19--64)1.1\* (1.0--1.1)0.0021.1 (1.0--1.2)0.166Separation anxiety disorder19 (10--31)19 (8--29)18 (8--30)14 (8--36)17 (8--28)1.0 (1.0--1.1)0.0741.0 (1.0--1.1)0.235Social anxiety disorder14 (9--18)13 (10--16)13 (8--16)13 (8--17)12 (7--15)1.2\* (1.1--1.2)\< 0.0011.3\* (1.3--1.4)\< 0.001Major depression/dysthymia38 (25--53)33 (22--48)34 (21--51)30 (18--50)29 (15--46)1.2\* (1.1--1.2)\< 0.0011.1\* (1.0--1.2)0.001Bipolar disorder25 (18--38)26 (18--44)28 (19--45)33 (20--45)24 (18--32)1.0 (1.0--1.1)0.1691.2\* (1.1--1.3)0.001Median age of onset was determined using the actuarial method. Differences in age of onset were tested with a discrete-time logistic regression, with the sample limited to participants who developed the comorbid disorder, and with number of early phobia subtypes time-varying until age 13\**p* \< 0.005

Impairment, suicidality, and serious mental illness {#Sec12}
---------------------------------------------------

Respondents without childhood SP reported a mean (SE) of 1.05 (0.03) days out of role in the past 30 days, compared to 1.80 (0.19) days among respondents with one SP subtype and 3.53 (0.53) days among those with 4+ subtypes (*B* = 0.56 (total sample) and 0.49 (SP subsample), *p* \< 0.001) (Table [5](#Tab5){ref-type="table"}). Suicidality was also relatively common among those with childhood SP, with 31.8% of those with 4+ subtypes reporting lifetime suicidal ideation, compared to only 7.5% of those without childhood phobia and 18.8% of those with one SP subtype (OR = 1.6 (total sample) and 1.3 (SP subsample), *p* \< 0.001). Furthermore, 36.8% of respondents with 4+ subtypes reported a 12-month SMI, compared to just 3.5% of those without childhood phobia and 12.7% of those with one subtype (OR = 2.1 (total sample) and 1.5 (SP subsample), *p* \< 0.001). PAFs for suicidality and SMI ranged from 13.9% for suicidal ideation to 20.4% for suicide attempts (Additional file [1](#MOESM1){ref-type="media"}: Table S3).Table 5Days out of role, suicidality, and serious mental illnessCategorySubcategoryNumber of subtypesTest of linear effect (total sample)Test of linear effect (SP cases only)01234+Mean (SE)Mean (SE)Mean (SE)Mean (SE)Mean (SE)*B* (SE)*p* value*B* (SE)*p* valueDays out of role in the past 30 days1.05 (0.03)1.80 (0.19)1.94 (0.17)2.51 (0.30)3.53 (0.53)0.56\* (0.06)\< 0.0010.49\* (0.15)\< 0.001% (SE)% (SE)% (SE)% (SE)% (SE)OR (95% CI)*p* valueOR (95% CI)*p* valueSuicidalityIdeation7.5 (0.1)18.8 (0.8)23.7 (1.3)30.7 (2.0)31.8 (2.4)1.6\* (1.6--1.7)\< 0.0011.3\* (1.2--1.3)\< 0.001Plan2.3 (0.1)6.7 (0.5)9.5 (0.8)13.6 (1.4)14.1 (1.8)1.7\* (1.6--1.8)\< 0.0011.3\* (1.2--1.4)\< 0.001Attempt2.0 (0.0)6.5 (0.4)8.4 (0.7)13.4 (1.3)16.8 (1.7)1.7\* (1.7--1.8)\< 0.0011.4\* (1.3--1.5)\< 0.001Serious mental illness3.5 (0.1)12.7 (0.7)20.9 (1.2)27.8 (2.1)36.8 (2.7)2.1\* (2.0--2.2)\< 0.0011.5\* (1.4--1.7)\< 0.001\**p* \< 0.005

Sensitivity analyses {#Sec13}
--------------------

Associations of SP subtype number with prevalence, persistence, and severity of secondary comorbid disorders were generally consistent across age groups (Additional file [1](#MOESM1){ref-type="media"}: Table S4 and 5), suggesting that the associations described above are generally stable over the life course. Likewise, we found associations of SP subtype number with the lifetime prevalence of comorbid disorders and suicidality in participants with and without a current 12-month internalizing disorder (Additional file [1](#MOESM1){ref-type="media"}: Table S6-S10). Finally, the prevalence of specific phobia, comorbid disorders, and suicidality were all lower in low- or middle-income countries compared to high-income countries; however, the associations between number of SP subtypes and comorbidity or suicidality were similar regardless of country income level (Additional file [1](#MOESM1){ref-type="media"}: Table S11-16).

Discussion {#Sec14}
==========

Principal findings {#Sec15}
------------------

In this study, we used a large cross-national sample to explore the associations of childhood generalized SP with the prevalence, persistence, and severity of other internalizing disorders. Among the 7.6% of participants reporting lifetime SP, most (78%) had already developed the disorder before age 13. Childhood SP was highly persistent, although severe disability and treatment-seeking for SP were uncommon. Many respondents with childhood SP reported multiple phobias (44%), with 8% even reporting four or more phobias. Childhood SP was strongly associated with prevalence, persistence, and severity of other internalizing disorders as well as with an early age of onset of these disorders. It was also associated with increased number of days out of role and SMI, as well as with suicidality. At a population level, 8.7--38.8% of all internalizing disorders and 13.9--20.4% of all suicidality or SMI were associated with childhood SP. Furthermore, associations persisted throughout the lifespan. Of particular importance, participants with generalized specific phobia had much worse outcomes than those with a single fear. For example, 17% of those with four or more phobias reported a suicide attempt, compared to only 7% of those with a single phobia.

SP is generally viewed as a relatively mild disorder that causes less disability than other mood or anxiety disorders \[[@CR24]\]. However, our results suggest that childhood SP, particularly when generalized, is strongly associated with poor long-term outcomes in the internalizing domain. Caution is needed since these results are based on a retrospective cohort design and recall error could lead to bias. However, the stability of the results across the age range of this very large and diverse sample suggests that the pattern is worthy of future investigation.

The present study is a practical application of suggestions made in the Hierarchical Taxonomy Of Psychopathology (HiTOP) initiative, which aims to develop an empirically driven nosology of psychopathology \[[@CR44]\]. One fundamental aspect of HiTOP is its reliance on quantitative, rather than dichotomous measures, to more closely approximate the true nature of psychopathology. Although we have examined a specific disorder, we have used a more quantitative approach than the strictly DSM approach by looking at the number of SP subtypes. Furthermore, we chose to focus on specific phobia because it tends to be the earliest manifestation of an internalizing liability, not because we think it is unique. The results suggest that it might be possible to identify at least some of the people with a strong internalizing liability in childhood even though their childhood disorders typically are not severe.

A similar approach could be applied to other psychopathology domains. For instance, the externalizing domain includes substance use disorders, which usually first appear in late adolescence, as well as disorders with childhood onset, such as attention deficit hyperactivity disorder (ADHD) \[[@CR3]\]. For other domains, such as thought disorders, subclinical psychotic experiences or personality traits like suspiciousness might be relevant \[[@CR45], [@CR46]\]. Examination of personality traits might also help refine the early identification of persons with high internalizing or externalizing liabilities.

From the point of view of prevention, one might argue whether targeted interventions should be aimed at everyone with childhood SP or at a smaller or larger group. If resources are limited, targeting those with multiple phobias is reasonable, as the tendency to generalize fear appears to predict a particularly poor prognosis. For instance, reducing the risk for just this very small group (0.5%) to that of people without childhood SP could prevent 1.1--7.8% of other internalizing disorders and 3.5% of all suicide attempts. However, even participants with a single phobia had increased risks of unfavorable outcomes. The population attributable fraction for suicide attempts for all childhood SP, for instance, was 20.4%, showing that much greater benefits could be obtained by targeting this larger group. Furthermore, previous research has found that most children reporting a specific fear do not meet SP criteria \[[@CR31]\]. It is currently unclear whether such fearfulness is harmless or a sign of an internalizing vulnerability, for instance when fearfulness is generalized.

As our study is observational, we cannot establish causality. We hypothesize that the associations are not directly causal, but that both childhood SP and later outcomes are expressions of a latent internalizing vulnerability. Although SP is a promising target in part because it is a relatively easy to treat disorder \[[@CR47]\] that nevertheless often remains untreated, it is unclear whether treatment specifically for SP would have substantial effects on internalizing outcomes later in life. Exposure is a common element in cognitive behavioral therapy, so broader effects on the underlying vulnerability are plausible, and there is some evidence to suggest that treatment for phobia can lead to improvement in already-existing comorbid anxiety disorders \[[@CR48]\]. Since even single-session behavioral therapy can be sufficient for SP \[[@CR49]\], and since up to 20% of suicide attempts and 19% of SMI are attributable to childhood SP (assuming a causal relationship), it would be highly worthwhile to examine whether early treatment of specific phobia has a substantial effect on these other outcomes.

In contrast to most previous research regarding SP, which used participant samples from high-income Western countries, our sample included a diverse set of countries. We found that both SP and our main outcomes, comorbidity and suicidality, were less prevalent in low- and middle-income countries than in high-income countries. However, the associations between childhood (generalized) SP and these outcomes were remarkably similar across country income levels. This suggests that childhood generalized SP might be a globally useful and not culturally specific marker for at-risk children. However, treatment rates for childhood-onset SP are even lower in low- or middle-income countries (12.7%) than in high-income countries (26.8%), and it may be difficult to detect and provide early intervention to these children if resources are scarce. Ideally, to reach as many people as possible, any screening or intervention program for childhood generalized SP should also be feasible in countries with relatively few specialist mental health care providers.

Strengths and limitations {#Sec16}
-------------------------

The World Mental Health Surveys provide a unique opportunity to examine childhood SP and its relationship to other internalizing disorders in a very large sample from a diverse set of countries using a common protocol and instrument. However, there are also several important limitations. First, data are derived from a cross-sectional interview of adult participants, and age of onset is therefore estimated retrospectively. While the survey was designed using modern cognitive interviewing methods as a way to encourage active memory search and improve recall accuracy \[[@CR50]\], some recall bias doubtlessly persists. Mild SP may have been forgotten, so our sample may not be fully representative of all children with SP. However, while some of our research questions could also be examined with existing longitudinal studies, no longitudinal studies with a sufficiently large sample size exists that could examine all the questions considered here. We also took several steps to investigate whether recall bias could explain our results. Firstly, we performed sensitivity analyses in the separate age groups and found broadly similar results in the youngest age group (18--34 years old), for whom recall bias should be least problematic, compared to the oldest age group (50+ years old). Presence of current psychopathology could also lead to recall bias. If respondents with current psychopathology are more likely to recall symptoms they suffered previously, including specific phobias, this could lead to a spurious association between childhood SP and comorbidity. However, we also found strong associations between number of childhood SP subtypes and lifetime comorbidity within the subgroup of respondents that did not report a 12-month internalizing disorder. Secondly, the observational design precludes causal inferences. Finally, the CIDI does not assess all phobias. Consequently, we may have underestimated the number of childhood SP subtypes.

Conclusions {#Sec17}
===========

In conclusion, this study has shown that childhood generalized SP, as assessed in a retrospective survey, is strongly associated with poor outcomes in the internalizing domain of psychopathology throughout the life course. While our study cannot establish whether childhood SP is causally associated with these later outcomes or whether some other factor, such as an underlying internalizing vulnerability, explains the association, it clearly identifies children with generalized SP as a high-risk group. Respondents with childhood SP not only were more likely than other respondents to develop internalizing disorders, but developed them at an earlier age and had a more persistent and severe course, including more disability, suicidality, and serious mental illness. Although even respondents with a single childhood SP subtype had an elevated risk of poor outcomes, risk was much higher among respondents who reported multiple childhood SP subtypes. Children with generalized SP might therefore be an important target group for early intervention to reduce internalizing psychopathology across the lifespan.
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ADHD

:   Attention deficit hyperactivity disorder

CI

:   Confidence interval

CIDI

:   Composite International Diagnostic Interview

DSM

:   Diagnostic and Statistical Manual of Mental Disorders

GAD

:   Generalized anxiety disorder

HiTOP

:   Hierarchical Taxonomy Of Psychopathology

IQR

:   Interquartile range

MDD

:   Major depressive disorder

OR

:   Odds ratio

PAF

:   Population attributable fraction

PTSD

:   Post-traumatic stress disorder

SCID

:   Structured Clinical Interview for DSM-IV

SD

:   Standard deviation

SDS

:   Sheehan Disability Scale

SE

:   Standard error

SMI

:   Serious mental illness

SP

:   Specific phobia

WMHS

:   World Mental Health Surveys
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